Peru Director Tecnico: Pharmacist Responsibility and Compliance Duties

Regulatory information verified as of October 29, 2026

1. Key takeaways

The technical director (Director Técnico) of a Peruvian pharmaceutical establishment (Establecimiento Farmacéutico) must be a qualified professional such as a Químico Farmacéutico (pharmacist). The legal responsibilities of this role are bound to the establishment itself: the technical director is not a nominal position but a statutory role that shares quality liability with the facility. The legal source for this qualification requirement is Ley N° 29459 (Ley de los Productos Farmacéuticos, Dispositivos Médicos y Productos Sanitarios, published on 2009-11-26); the specific article number is pending verification, and the official publication governs. For foreign manufacturers selecting a Peruvian holding partner, the technical director is therefore a substantive compliance variable rather than a formality, because the effectiveness of the facility license, the responsiveness of the pharmacovigilance chain, and the credibility of the establishment during inspections all depend on this individual being genuinely present and able to perform.

When GRZAN evaluates a potential cooperation holding entity, it verifies whether the technical director is in post and has sufficient time to perform the role with the same weight as the facility license itself, because a license without an operating professional is a paper asset that fails exactly when it is needed most.

2. Legal basis

Regulatory information verified as of October 29, 2026.

3. Expert insights

Insight one: the liability binding is person plus facility, not person plus product. The institutional design of the technical director role places quality liability on a natural person who can be pursued within Peru. Mechanically, the facility license of a pharmaceutical establishment is granted under D.S. N° 014-2011-SA, while day-to-day compliant operation of the facility is endorsed by the signature of the technical director. Once storage conditions go out of control, the cold chain is broken, or vigilance obligations are not fulfilled, the path of accountability points simultaneously at the establishment and at the technical director. This is a different line of liability from the responsibility that the registration holder (Titular del Registro Sanitario, PRH) bears for the product, and the two are easily conflated in practice.

Insight two: the pharmacist qualification requirement shapes the cost structure of holding entities. Químico Farmacéutico is a regulated professional qualification that cannot be substituted by a quality system engineer or a regulatory affairs specialist. This means that the number of products a Droguería (wholesale distributor) can carry is constrained by the actual working capacity of its technical director, not by its registered capital. GRZAN treats the question of how many establishments a technical director simultaneously serves as a due diligence item, because excessive concurrent appointments directly weaken the capacity for on-site handling of regulatory events.

Insight three: presence requirements are an extension of making the license substantive. DIGEMID Comunicado N° 012-2026 (2026-08-25, secondary source, from an industry database, pending verification) concerns establishment availability and technical director presence requirements. Mechanically, if the regulator treats presence as an inspection item, the absence of the technical director is no longer a personnel management issue but a potential defect in establishment availability, which in turn affects the enforceability of the sanitary registrations (Registro Sanitario, RS) registered under that establishment.

Insight four: the connection point with vigilance obligations. Under R.M. N° 539-2016/MINSA (Norma Sanitaria que Regula las Actividades de Farmacovigilancia y Tecnovigilancia de Productos Farmacéuticos, Dispositivos Médicos y Productos para la Salud, published on 2016-07-27), serious adverse events must be reported within 24 hours, and moderate or mild suspected adverse events within 20 calendar days. The establishment where the technical director works is the actual execution end of the domestic reporting chain. Whether the 24-hour window can be met depends on whether someone is present at the establishment, not on the reaction speed of the foreign manufacturer. A manufacturer abroad can accelerate document production, but it cannot compress a reporting clock that starts at the establishment; the only reliable way to protect the window is to make sure the establishment is staffed and instructed before any product reaches the market.

4. Practical recommendations

1. Before engaging a holding entity, request the professional qualification certificate of its technical director together with the current appointment document, and check that the professional category is a qualified professional such as a Químico Farmacéutico.
2. In the holding service agreement, stipulate notification obligations and transition arrangements for changes of technical director, so that no liability vacuum period arises.
3. Verify whether the technical director holds concurrent posts at multiple establishments, and assess the time actually available for this project.
4. Establish a vigilance communication line that connects directly with the establishment technical director, so that the 24-hour serious adverse event reporting window is executable.
5. Keep tracking the technical director presence requirements addressed in DIGEMID Comunicado N° 012-2026, mark them as pending verification, and confirm on-site arrangements before inspections.

5. Verification checklist

□ The professional qualification of the technical director has been checked as a qualified professional such as a Químico Farmacéutico.

□ The current appointment document and an explanation of available working time have been obtained.

□ The corresponding article number of Ley N° 29459 has been marked as governed by the official publication.

□ A reporting communication mechanism covering both the 24-hour and 20 calendar day windows has been established.

□ Progress on the primary verification of the presence requirements in DIGEMID Comunicado N° 012-2026 is being tracked.

□ Regulatory information verified as of October 29, 2026.

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration support in Peru for manufacturers, importers, and authorized representatives. For inquiries, contact info@grzanglobal.com.

*GRZAN Regulatory Affairs Team*